Healthier and sustainable food ingredien...As food producers are taking up current health and sustainability trends more and more, the next EFIB (30 September??2 October, 2019) will see a lot of technology providers and ingredient producers … more ➔
Patent Ineligibility InitiativeBy Ute Kilger, Patent Attorney, European Patent and Trade Mark Attorney, Boehmert & Boehmert Anwaltspartnerschaft mbB The Life Science Industry needs a strong, predictable, reliable patent system … more ➔
Emergency on planet AMR: a vital pipeline... The recently released IACG report testifies that the antimicrobial resistance (AMR) problem is now receiving some echo at the political level. Literature exploring ways to fix the acknowledged market … more ➔
Functional sugars made by biotech for ever... Rare functional sugars provide huge market opportunities. European Biotechnology spoke with Stefan Jennewein, Founder and CEO of Jennewein Biotechnologies, about the companys strategy and its latest … more ➔
Lessons from a former poster child With partner Indivior exchanging a late-stage addiction programme for early-stage alternatives, 2019 did not start exceptionally well for Addex Therapeutics. But, the Swiss drug developer has shown … more ➔
A national bioeconomy strategy for Austria Within the record time of nine months, the Austrian government, together with experts of the Austrian Bioeconomy plattform and the sustainability think tank Denkstatt, has worked out a national bioeconomy … more ➔
Encourage development of new antimicrobial... Antimicrobial resistance (AMR) is a global threat, particularly given the modest activity in the pipeline of new antimicrobials in development, and emerging resistance to existing antibiotics. In 2016, … more ➔
Serialisation using labelsAccording to the FMD 2011/62, serialisation of all prescription drug packs in Europe will inevitably become a daily routine for the pharmaceutical industry from 2019. European Biotechnology spoke with … more ➔
A unique approach to bring open innovati...In February, Johnson & Johnson Innovation, JLABS opened its first European open innovation incubator, JLABs @ BE, at the heart of the Beerse Janssen R&D Campus in Belgium. European Biotechnology … more ➔
Diversifying into oncology if ROI on bugs...Big Pharmas interest in R&D on anti-infectives declined when other areas like oncology began offering higher returns. A few biotechs mirror pharma (Basilea, Idorsia and Polyphor), but could stay … more ➔
